Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older.
• People whose doctors estimate they have a life expectancy of more than three months.
• People who are well enough to carry out basic daily activities, as measured by a standard cancer performance scale (a score of 0, 1, or 2 on the ECOG scale — confirm with trial site if unsure what this means).
• People whose liver, kidneys, and other organs are functioning at a level acceptable to the study team, based on blood test results.
• People who have multiple myeloma that has come back or stopped responding to treatment, and who have already been through at least two prior rounds of treatment for their myeloma.
• People who have previously been treated with certain myeloma medicines, including lenalidomide, bortezomib, daratumumab, elotuzumab, pomalidomide, and/or carfilzomib.
• People who have NOT previously had CAR T-cell therapy and whose myeloma stopped responding to either carfilzomib or pomalidomide — but not both at the same time.
• People whose most recent treatment WAS a specific type of CAR T-cell therapy targeting a protein called BCMA, and whose myeloma has since progressed — regardless of how their myeloma responded to carfilzomib or pomalidomide previously.
• People whose myeloma can be measured through specific blood, urine, or protein tests that meet the levels set out by the study team.
• People whose side effects from previous cancer treatments have mostly resolved (settled to a mild level), with the exception of hair loss and mild nerve-related symptoms, which are allowed.
• People who are able to understand the study and are willing to give written consent to participate.
• People who are willing to follow the safety program requirements linked to two of the study drugs, belantamab mafodotin and pomalidomide.
• People whose insurance has approved coverage for pomalidomide and dexamethasone.
• Female participants who are willing to follow local guidelines on contraception during clinical trials.
• Male participants who agree to avoid donating sperm and to follow local contraception guidelines — including using a condom (even after a vasectomy) or remaining abstinent — during the treatment period and for six months after the last dose.

Who may not be able to join:

• People who have certain other blood or plasma cell conditions, such as Waldenström's macroglobulinemia, systemic amyloidosis, POEMS syndrome, or plasma cell leukaemia.
• People who have had radiation treatment to multiple areas of the body within the three weeks before starting the trial (radiation to a single site at least one week before may be acceptable — confirm with trial site).
• People who have taken any other experimental drug or standard myeloma treatment, including steroids, within 14 days before the first dose of the trial drug.
• People whose myeloma previously stopped responding to belantamab mafodotin.
• People with active corneal eye disease beyond very mild changes (confirm with trial site).
• People with unstable liver or bile duct disease, such as fluid build-up in the abdomen, confusion related to liver failure, jaundice, or cirrhosis.
• People with an active kidney condition, including kidney infection or the need for dialysis, that could affect their safety during the trial.
• People who wear contact lenses, unless an eye specialist specifically advises otherwise during the trial.
• People who are currently enrolled in another interventional clinical trial.
• People who have had major surgery within two weeks before starting the trial.
• People with any signs of active bleeding from body surfaces or internal organs.
• People with significant nerve damage or nerve pain (grade 3–4, or grade 2 with pain) at the time of starting the trial.
• People with certain serious or uncontrolled heart conditions, including uncontrolled irregular heartbeat, a heart attack or certain heart procedures within the past three months, severe heart failure (Class III or IV), or uncontrolled high blood pressure.
• People who have had a known allergic or serious reaction to belantamab mafodotin or chemically similar drugs, or to any component of the study treatment.
• People with an active infection that requires treatment.
• People living with HIV, unless specific criteria related to immune cell levels, viral load, and overall health are met — as assessed by the study doctor.
• People with Hepatitis B, unless specific clinical criteria confirmed by the study doctor are met.
• People with an active or unresolved Hepatitis C infection, unless they have successfully completed antiviral treatment and meet specific testing requirements (confirm with trial site).
• People with another active cancer, unless the second cancer has been medically stable for at least two years and is not expected to interfere with the study. People with certain treated skin cancers may be eligible without the two-year waiting period (confirm with trial site).
• People who are pregnant or breastfeeding.
• People with serious or unstable medical or psychiatric conditions that could affect their safety, their ability to give informed consent, or their ability to follow the study requirements.

Important: Always verify eligibility with the trial site directly before applying.